[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. França CM, Caran EM, Alves MT, Barreto AD, Lopes NN: Rhabdomyosarcoma of the oral tissues--two new cases and literature review. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E136-40
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the oral tissues--two new cases and literature review.
  • Rhabdomyosarcoma (RMS) is a malignant soft tissue neoplasm consisting of cells derived from the primitive mesenchyme that exhibit a profound tendency to myogenesis.
  • The use of contemporary, multi-agent chemotherapy, radiotherapy, and surgery has made treatment of the disseminated disease possible, and has significantly improved overall survival from 25% in 1970 to 70% in 1991.
  • Here, we present the management of two cases of orofacial RMS in adolescents: an 18-year-old, white female that had a 9-month history of a nodule in the left buccal mucosa, and a 19-year-old, white male who had been aware of a nodule in the left, posterior maxillary ridge with progressive growth for 4 months.
  • Before final diagnosis, both cases were previously treated as inflammatory lesions.
  • Their clinicopathological aspects, treatment, and poor survival as a consequence of delays in diagnosis are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505791.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 15
  •  go-up   go-down


2. Wu Z, Huang X, Kang F: [The neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2003 Jun;21(3):194-6
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa].
  • OBJECTIVE: The purpose of this study was to discuss the principle in neck treatment of cN0 patients with squamous cell carcinoma of buccal mucosa.
  • METHODS: 101 patients of squamous cell carcinoma of buccal mucosa at the stage of cN0, who had hospitalized in West China College of Stomatology, Sichuan University from 1980 to 2000, were investigated retrospectively.
  • All the patients received a comprehensive therapy consisting of surgical procedures combined with chemotherapy and radiotherapy.
  • The combining radical therapy of buccal, mandible and neck was the main surgical method.
  • CONCLUSION: The rate of occult metastasis of squamous cell carcinoma of buccal mucosa is high, and then we should adopt actively selective neck dissection for the cN0 patients of squamous cell carcinoma of buccal mucosa.
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Mouth Mucosa / surgery. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12898760.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Misra S, Chaturvedi A, Misra NC: Management of gingivobuccal complex cancer. Ann R Coll Surg Engl; 2008 Oct;90(7):546-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The search terms carcinoma oral cavity, and cancer oral cavity, buccal mucosa, gingiva, gingivobuccal complex, and alveolus cancer/carcinoma were used.
  • RESULTS: Treatment of gingivobuccal complex cancer is primarily surgical.
  • Radical neck dissection, or its modification, is the standard treatment for the node-positive neck.
  • Supraomohyoid neck dissection is the accepted treatment for the node-negative neck.
  • Radiotherapy is usually not the preferred modality of treatment for early gingivobuccal complex cancer.
  • It is used either as postoperative adjuvant treatment or as definitive treatment for advanced cancer with or without chemotherapy.
  • Chemotherapy has been used as neo-adjuvant, adjuvant or palliative treatment.
  • Advanced cancers constitute a major proportion of patients presenting for treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Gingival Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neck Dissection / methods. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] JAMA. 2007 Jul 4;298(1):70-82 [17609492.001]
  • [Cites] Br J Oral Maxillofac Surg. 2001 Dec;39(6):411-8 [11735134.001]
  • [Cites] Head Neck. 2002 Mar;24(3):282-9 [11891961.001]
  • [Cites] Lancet Oncol. 2000 Sep;1(1):37-42 [11905687.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):199-203 [7782204.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(3):143-5 [7662347.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):119-23 [7558808.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jun;122(6):634-8 [8639295.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):502-4 [8903493.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):650-3 [8988669.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):654-7 [8988670.001]
  • [Cites] Am J Surg. 1998 Nov;176(5):422-7 [9874426.001]
  • [Cites] Head Neck. 1999 Jan;21(1):39-42 [9890349.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Head Neck. 1999 Mar;21(2):104-10 [10091977.001]
  • [Cites] Br J Oral Maxillofac Surg. 1999 Jun;37(3):205-9 [10454028.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):73-7 [10456709.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):778-85 [15599855.001]
  • [Cites] Lancet Oncol. 2001 May;2(5):261-9 [11905780.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 May;128(5):600-3 [12003599.001]
  • [Cites] Head Neck. 2002 Oct;24(10):921-4 [12369070.001]
  • [Cites] Oncology. 2002;63(4):338-45 [12417788.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] World J Surg. 2003 Jul;27(7):805-10 [14509511.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Nov;61(11):1289-96 [14613085.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Dec;129(6):713-9 [14663440.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1743-52 [15117998.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):3-10 [15124127.001]
  • [Cites] Semin Oncol. 2004 Jun;31(3):382-93 [15190496.001]
  • [Cites] Eur J Surg Oncol. 2004 Sep;30(7):804-6 [15296998.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):365-73 [15380568.001]
  • [Cites] Head Neck. 2004 Oct;26(10):897-902 [15390193.001]
  • [Cites] Head Neck Surg. 1987 Jan-Feb;9(3):157-61 [3623945.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1326-31 [3345488.001]
  • [Cites] Indian J Cancer. 1987 Sep;24(3):167-71 [3450582.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):111-22 [2722487.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):476-82 [2258286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):17-21 [8416876.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(1):11-7 [8466744.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):958-63 [8357596.001]
  • [Cites] Indian J Cancer. 1993 Dec;30(4):176-80 [8206500.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):391-4 [7977957.001]
  • [Cites] Br J Oral Maxillofac Surg. 1994 Dec;32(6):347-59 [7848993.001]
  • [Cites] Indian J Cancer. 1994 Dec;31(4):235-9 [7875724.001]
  • [Cites] Br J Oral Maxillofac Surg. 1995 Feb;33(1):3-8 [7718525.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):413-6 [10722019.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):37-46, viii [15649497.001]
  • [Cites] Head Neck. 2005 Jul;27(7):597-602 [15825204.001]
  • [Cites] Head Neck. 2005 Sep;27(9):739-47 [16047368.001]
  • [Cites] Oral Oncol. 2006 Jan;42(1):14-25 [15979381.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Mar;6(3):405-17 [16503857.001]
  • [Cites] Head Neck. 2001 Oct;23(10):907-15 [11592239.001]
  • (PMID = 18701010.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 57
  • [Other-IDs] NLM/ PMC2728300
  •  go-up   go-down


Advertisement
4. Badakh DK, Grover AH: The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins. Indian J Cancer; 2005 Jan-Mar;42(1):51-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of postoperative radiation therapy in patients with carcinoma of the buccal mucosa and lower alveolus with positive surgical margins.
  • PURPOSE: A retrospective analysis to determine the efficacy of postoperative radiation therapy, in patients of carcinoma of the buccal mucosa and lower alveolus with pathologically verified positive surgical margins (PSM).
  • MATERIALS AND METHODS: Ninety-four patients were analysed, who underwent surgery plus postoperative radiation therapy.
  • CONCLUSION: To conclude in our study median dose of 60 Gy in PSM patients was not able to improve DFS and showed poor results as compared with NSM patients.
  • There is also evidence from other studies, to suggest that post-operative radiation doses upto 60 Gy may not be sufficient to overcome this poor prognostic factor.
  • In physically fit patients we are trying to administer concomitant chemotherapy along with radiation treatment.
  • [MeSH-major] Mouth Neoplasms / epidemiology. Mouth Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. India / epidemiology. Lymphatic Metastasis. Male. Medical Records. Middle Aged. Mouth Mucosa / pathology. Neoplasm, Residual / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805693.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] India
  •  go-up   go-down


5. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J: Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology; 2002;63(4):338-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
  • OBJECTIVES: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy.
  • All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue).
  • Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion.
  • Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed.
  • RESULTS: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial.
  • One hundred ninety-four patients (95%) completed 2 courses of chemotherapy.
  • After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery.
  • Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients.
  • A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013).
  • CONCLUSIONS: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12417788.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Wang HM, Ng SH, Wang CH, Liaw CT, Chen JS, Yang TS, Chen IH: Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa. Anticancer Drugs; 2001 Apr;12(4):331-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
  • From July 1994 to December 1996, 41 patients with previously untreated, advanced bulky squamous cell carcinoma arising from the buccal mucosa (BSCC) were enrolled.
  • The tumor extent was stage III/IV: three of 38, T4: 85%, N2-3: 20%.
  • Patients were initially scheduled to receive intra-arterial (i.a.) chemotherapy, followed by i.v. chemotherapy and regional therapy.
  • The i.a. chemotherapy catheter was properly placed by external carotid artery angiography via the femoral artery.
  • The i.a. chemotherapy consisted of cisplatin (P) 100 mg/m(2) day 1 plus 5-fluorouracil (F) 1000 mg/m(2) day 1-4, and the i.v. chemotherapy consisted of PF (10 patients) or PF plus methotrexate 200 mg/m(2) day 15 and 22 (31 patients).
  • All chemotherapy regimens were administered at 4-week intervals.
  • The response rate of i.a. plus i.v. chemotherapy for the primary site was 85% (35 of 41) with 29% complete remission (CR) (12 of 41).
  • Major toxicity from i.a. chemotherapy of WHO grade > or = 3 included: mucositis of infusion area (76%), hemialopecia (56%) and leukopenia (5%).
  • Three neurologic complications of i.a. chemotherapy including one hemiparesis occurred.
  • The median follow-up time was 47 months (range 36-66 months), and the overall survival and disease-free survival were both 34% (14 of 41).
  • Four patients were cured with chemotherapy alone and eight patients (19.5%) were cured without surgical intervention.
  • Using i.a. chemotherapy as a cytoreductive therapy followed by subsequent i.v. chemotherapy produces a high response rate and an encouraging degree of complete response rate in advanced bulky BSCC.
  • However, toxicity management and catheter placement will need to be improved in order to better define the role of this therapy in advanced BSCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Eruptions / etiology. Dyspnea / chemically induced. Dyspnea / drug therapy. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial / methods. Infusions, Intravenous / methods. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Middle Aged. Mouth Mucosa. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Stomatitis / chemically induced. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11335789.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


7. Rosell R, Taron M, Alberola V, Massuti B, Felip E: Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer; 2003 Aug;41 Suppl 1:S97-102
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic testing for chemotherapy in non-small cell lung cancer.
  • Cisplatin or carboplatin is commonly used with gemcitabine, docetaxel, paclitaxel, or vinorelbine as chemotherapy doublets in the treatment of advanced non-small-cell lung cancer (NSCLC).
  • This lack of evidence for improvement in survival with any chemotherapy regimen has created a tabula rasa where no more large randomized trials should be conducted without including a genetic analysis.
  • For a long time, ERCC1 mRNA levels have been known to correlate with DNA repair capacity in various tissues.
  • Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia.
  • An ongoing customized ERCC1-based chemotherapy trial has been designed based on this knowledge.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. DNA Helicases. DNA Repair. DNA-Binding Proteins. Deoxycytidine / analogs & derivatives. Genetic Testing. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Protein Biosynthesis. Transcription Factors
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / pharmacology. Clinical Trials as Topic. DNA Adducts. DNA Damage. Drug Resistance, Neoplasm. Endonucleases. Humans. Polymorphism, Genetic. RNA, Messenger / biosynthesis. Repressor Proteins. Survival Analysis. Taxoids / administration & dosage. Taxoids / pharmacology. Treatment Outcome. Xeroderma Pigmentosum Group D Protein

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12867068.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Taxoids; 0 / Transcription Factors; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 23
  •  go-up   go-down


8. Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A: Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. Clin Cancer Res; 2007 Nov 1;13(21):6518-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
  • PURPOSE: To evaluate the role of pretreatment and posttreatment expression in buccal mucosa cells of signal transduction proteins activated by epidermal growth factor receptor, including phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated mitogen-activated protein kinase (p-MAPK), and phosphorylated AKT (p-AKT), in predicting gefitinib activity in advanced non-small cell lung cancer patients.
  • Expression of the same proteins was also assessed on corresponding tissue samples for comparison.
  • EXPERIMENTAL DESIGN: Protein expression was evaluated by standard immunocytochemistry in buccal smears, obtained by scraping immediately before and after 2 weeks of gefitinib treatment, and in the available archival tumor specimens.
  • Toxicity (P = 0.025) and baseline p-AKT expression in buccal mucosa cells (P = 0.061) showed a potential predictive role.
  • On the contrary, the probability of achieving an objective response was not affected by pretreatment expression of EGFR, p-EGFR, and p-MAPK, either in buccal mucosa or in tumor tissue.
  • Responders showed a nonstatistically significant trend toward a more pronounced reduction in the expression of p-EGFR, p-MAPK, and p-AKT after gefitinib treatment.
  • CONCLUSIONS: Epithelial cells obtained from buccal mucosa may be used to assess the pharmacodynamic effect of EGFR-targeted agents, and pretreatment p-AKT expression may be a possible predictive biomarker of in vivo gefitinib activity.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Screening Assays, Antitumor / methods. Lung Neoplasms / drug therapy. Mouth Mucosa / cytology. Mouth Mucosa / metabolism. Quinazolines / pharmacology
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry / methods. MAP Kinase Signaling System. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins p21(ras) / metabolism. Receptor, Epidermal Growth Factor / metabolism. Signal Transduction. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975165.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); S65743JHBS / gefitinib
  •  go-up   go-down


9. Yamamoto K, Obara S, Mishima K, Nakamura H, Yoshimura Y: [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. Gan To Kagaku Ryoho; 2004 Apr;31(4):635-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
  • We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1.
  • We carried out chemotherapy with TS-1 50 mg/day, without surgical treatment.
  • The tumor disappeared clinically at 4 months after 3 courses of the TS-1 administration.
  • Adverse drug reactions, including vomiting, leukopenia and thrombopenia, forced a stop of the administration of TS-1.
  • Although she finally died of in senescence 2 months from the cease of administration, there was no recurrence of the cancer at the time.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Female. Humans. Leukopenia / chemically induced. Mouth Mucosa / pathology. Neoplasm Invasiveness. Remission Induction. Thrombocytopenia / chemically induced. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


10. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Their 5-year survival in relation to age, gender, tumor site, lymph node involvement, presence of distant metastasis, staging, differentiation, and risk factors, including betel quid (BQ) chewing, cigarette smoking, and alcohol consumption, was analyzed.
  • Tumors occurred mainly at the buccal mucosa (BM) (100 of 378, 26.5%), gingiva (105 of 378, 27.8%), and tongue (103 of 378, 27.2%).
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Vorob'ev IuI, Garbuzov MM, Retinskaia II, Popov NV: [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa]. Stomatologiia (Mosk); 2000;79(1):36-8
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical picture, diagnosis and radiation treatment principles in cancer of the buccal mucosa].
  • Diagnosis and treatment of 228 patients with cancer of the buccal mucosa is analyzed.
  • For cosmetic reasons, radiotherapy (oral x-ray therapy, interstitial method, long-distance gamma beam therapy) was the method of choice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Carcinoma / diagnosis. Carcinoma / radiotherapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / diagnosis. Mouth Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cheek. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Mouth Mucosa. Neoplasm Staging. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10693346.001).
  • [ISSN] 0039-1735
  • [Journal-full-title] Stomatologii︠a︡
  • [ISO-abbreviation] Stomatologiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] RUSSIA
  •  go-up   go-down


12. Yamaguchi S, Nagasawa H, Suzuki T, Fujii E, Iwaki H, Takagi M, Amagasa T: Sarcomas of the oral and maxillofacial region: a review of 32 cases in 25 years. Clin Oral Investig; 2004 Jun;8(2):52-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sarcomas were located in the maxilla including the maxillary sinus (n= 13), mandible (n= 13), buccal mucosa (n= 3), temporomandibular fossa (n= 2), and submandibular region (n= 1).
  • Surgery is the most reliable treatment for sarcomas of the oral and maxillofacial region.
  • Adequate excision with safety surgical margin as the initial therapy is important for better survival.
  • The value of radiation therapy and/or chemotherapy is uncertain.
  • [MeSH-minor] Adult. Age Factors. Aged. Child. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / epidemiology. Humans. Infant. Japan / epidemiology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Osteosarcoma / epidemiology. Retrospective Studies. Rhabdomyosarcoma / epidemiology. Sex Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1992 Jan-Feb;14(1):1-7 [1624288.001]
  • [Cites] Semin Surg Oncol. 1988;4(1):13-9 [3353619.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):367-72 [2802043.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1437-51 [2646010.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):201-7 [8318414.001]
  • [Cites] Oral Oncol. 1998 Jul;34(4):292-6 [9813725.001]
  • [Cites] Cancer. 1986 May 15;57(10):2070-6 [3955515.001]
  • [Cites] Jpn J Clin Oncol. 1988 Sep;18(3):231-4 [3411787.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):373-7 [2802044.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):198-200 [3276633.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3735-41 [11268447.001]
  • [Cites] Br J Oral Maxillofac Surg. 1992 Apr;30(2):115-8 [1567797.001]
  • [Cites] Eur J Surg Oncol. 2000 Mar;26(2):145-8 [10744932.001]
  • (PMID = 15281217.001).
  • [ISSN] 1432-6981
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Tucci R, Aburad De Carvalhosa A, Anunciação G, Daumas Nunes F, Dos Santos Pinto D Jr: Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol; 2010 Jan-Feb;59(1-2):55-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late diagnosis of a primary oral malignant melanoma: a case report.
  • Eighty percent of the cases are located on the palate and maxillary gingiva, with the remainder found on the mandibular gingiva, buccal mucosa, tongue, and floor of the mouth.
  • OMM are highly aggressive with the tendency to metastasize and invade the surrounding tissues more readily than other oral malignancies.
  • The usual therapeutic approach for OMM is surgical excision of the primary tumor, supplemented by radiotherapy, with chemotherapy and immunotherapy serving as adjuvant.
  • Palpation revealed a painless soft tissue arising in maxillary gingiva, extending to the palate and vestibular mucosa.
  • The patient underestimated his symptoms and look for treatment after a substantial growth of the lesion.
  • This is an example of how a delayed detection affects the prognosis of OMM.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Delayed Diagnosis. Denial (Psychology). Fatal Outcome. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212410.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Gkoulioni V, Eleftheriadou A, Yiotakis I, Ferekidou E, Chrisovergis A, Lazaris ACh, Kandiloros D: The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model. Anticancer Res; 2010 Jul;30(7):2891-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of imiquimod on dysplastic lesions of the oral mucosa: an experimental model.
  • AIM: To study the potent efficacy of the immunomodulatory agent imiquimod when applied on dysplastic lesions of the oral mucosa.
  • MATERIALS AND METHODS: Carcinogen (DMBA) was applied to the mucosa of the left buccal pouch of 26 male Wistar rats for 8 weeks, until dysplastic lesions were observed and histologically diagnosed.
  • Biopsies were taken before and after treatment.
  • In one case, a well-differentiated squamous cell carcinoma was converted to a papilloma-like squamous neoplasm with a benign morphology.
  • CONCLUSION: Our results indicate that imiquimod may be effective in treatment of precancerous lesions of the oral mucosa and thus inhibit the progress of carcinogenesis.
  • [MeSH-major] Aminoquinolines / pharmacology. Mouth Neoplasms / prevention & control. Precancerous Conditions / drug therapy
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene. Animals. Antineoplastic Agents / pharmacology. Carcinogens. Carcinoma, Squamous Cell / chemically induced. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Male. Mouth Mucosa / drug effects. Mouth Mucosa / pathology. Rats. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683029.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 99011-02-6 / imiquimod
  •  go-up   go-down


15. Yücel A, Cinar C, Aydin Y, Senyuva C, Güzel Z, Cetinkale O, Altintaŝ M: Malignant tumors requiring maxillectomy. J Craniofac Surg; 2000 Sep;11(5):418-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary site of tumor was adjacent skin in 53%, maxillary sinus or maxilla in 20%, palate and alveolar arch in 13%, lip and buccal mucosa in 13%, and mandible in 1% of the cases.
  • Postoperative radiotherapy was performed in 32 patients and combined radiotherapy and chemotherapy in 12 patients.
  • Resection of the tumor with free surgical margins and appropriate evaluation of the surgical defect for the most suitable reconstruction are the mainstays of treatment of the midfacial tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Facial Neoplasms / surgery. Female. Humans. Lip Neoplasms / surgery. Male. Mandible / surgery. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Maxillary Sinus Neoplasms / surgery. Middle Aged. Mouth Neoplasms / surgery. Neck Dissection. Neoplasm Recurrence, Local / surgery. Orbit Evisceration. Palatal Neoplasms / surgery. Palatal Obturators. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314064.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Jenwitheesuk K, Surakunprapha P, Chowchuen B, Tangvoraphongchai V, Pesee M, Krusun S, Supaadirek C: Results of multidisciplinary therapy of squamous cell carcinoma of the buccal mucosa at Srinagarind Hospital, Thailand. J Med Assoc Thai; 2010 Nov;93(11):1262-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multidisciplinary therapy of squamous cell carcinoma of the buccal mucosa at Srinagarind Hospital, Thailand.
  • OBJECTIVE: Review the clinical presentation and treatment of buccal carcinoma and compare it to the results of treatment as per survival rate.
  • MATERIAL AND METHOD: The authors reviewed the medical records of newly diagnosed seen between 1995 and 2005 at the Division of Plastic Surgery and the Department of Radiotherapy, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University Patients previously treated elsewhere or those whose lesions secondarily involved the buccal mucosa were excluded.
  • RESULTS: The authors reviewed the medical records of 107 buccal carcinoma patients (94 females and 13 males) averaging 67 years of age.
  • A combined modality treatment (surgery and radiation or chemotherapy) was used to treat the advanced stage (III and IV) patients.
  • The rate of incomplete therapy was high (47.78%).
  • In the group that completed the protocol (i.e., neoadjuvant, surgery, and post operative radiation), there were five patients for whom the 5-year survival seemed higher than the patients who followed the standard treatment of surgery and post-operative radiation but it was not statistically significant.
  • CONCLUSION: The treatment of buccal carcinoma requires a multidisciplinary team approach because most of the patients are elderly and present with an advanced stage.
  • If treatment continues through to completion of the protocol, the survival rate would increase.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Mucosa / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Thailand

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114204.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


17. Rosell R, Taron M, Camps C, López-Vivanco G: Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc); 2003 Oct;39(10):775-86
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cisplatin or carboplatin is commonly used with gemcitabine, docetaxel, paclitaxel or vinorelbine as chemotherapy doublets in the treatment of advanced non-small cell lung cancer.
  • This lack of evidence for improvement in survival with any chemotherapy regimen has created a tabula rasa in which no more large randomized trials should be conducted with out including a genetic analysis.
  • Patients see survival as their major concern, and other considerations, such as cost of treatment and qualify of life, are relegated to lower positions.
  • For a long time, ERCC1 mRNA levels have been known to correlate with DNA repair capacity in various tissues.
  • Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia.
  • An ongoing customized ERCC1-based chemotherapy trial has been established on this knowledge.
  • At the preclinical level, ERCC1 and XPD mRNA expression correlate with each other, and overexpression of XPD causes selective cisplatin resistance in human tumor cell lines.
  • In our experience, time to disease progression is significantly higher in gemcitabine/cisplatin-treated patients with the Lys751Gln genotype (9.6 months) than in those with the Lys751Lys genotype (4.2 months; p = 0.03).
  • This highlights the possibilities of individually tailored chemotherapy.
  • Patients with Lys751Lys had a longer time to progression.
  • At least 50% of non-small cell lung cancer patients harbor Lys751Lys and can benefit from docetaxel/ cisplatin treatment.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cisplatin / pharmacology. Cisplatin / therapeutic use. Clinical Trials as Topic. DNA Adducts / metabolism. DNA Repair. Drug Resistance, Neoplasm / genetics. Genetic Markers. Humans. Polymorphism, Genetic. Proteins / genetics. Ribonucleotide Reductases / genetics. Survival Rate. Xeroderma Pigmentosum Group D Protein

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14668933.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / Proteins; 0 / Transcription Factors; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 54
  •  go-up   go-down


18. Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, Lee MS, Hsiao M, Lin SK: Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol; 2003 Jan;39(1):19-26
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes.
  • In this study, multi-parameter assessments of morphological alterations, clonogenic efficiency, cell growth curves, DNA synthesis, and DNA strand break were employed to determine and compare the cytotoxic effects of NCTD on oral cancer KB cell line and normal buccal keratinocytes.
  • Normal buccal keratinocytes were more resistant to NCTD induced cytotoxicity.
  • The IC(50) of 24 h NCTD treatment for KB and keratinocytes were 15.06 and 216.29 microg/ml, respectively with a keratinocyte/KB selective index of 14.36.
  • In addition, inhibition of colony formation was noted in KB cells even when exposed to low concentration of drug (5 microg/ml) for a short period of time (6 h).
  • The underlying mechanisms of the differential actions of NCTD on these two cell types are worthy of further investigations.
  • [MeSH-major] Bicyclo Compounds, Heterocyclic / therapeutic use. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Cell Division / drug effects. DNA Damage. DNA, Neoplasm / biosynthesis. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Keratinocytes / drug effects. Mouth Mucosa. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12457717.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bicyclo Compounds, Heterocyclic; 0 / DNA, Neoplasm; 5442-12-6 / norcantharidin
  •  go-up   go-down


19. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM: Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol; 2004 Aug 1;22(15):3080-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
  • PURPOSE: To evaluate changes in epidermal growth factor receptor (EGFR) phosphorylation and its downstream signaling in tumor and surrogate tissue biopsies in patients with metastatic breast cancer treated with erlotinib, an EGFR tyrosine kinase inhibitor, and to assess relationships between biomarkers in tumor and normal tissues and between biomarkers and pharmacokinetics.
  • Ki67, EGFR, phosphorylated EGFR (pEGFR), phosphorylated mitogen-activated protein kinase (pMAPK), and phosphorylated AKT (pAKT) in 15 paired tumor, skin, and buccal mucosa biopsies (at baseline and after 1 month of therapy) were examined by immunohistochemistry and analyzed quantitatively.
  • RESULTS: The stratum corneum layer and Ki67 in keratinocytes of the epidermis in 15 paired skin biopsies significantly decreased after treatment (P = .0005 and P = .0003, respectively).
  • In the EGFR-positive tumor, pEGFR, pMAPK, and pAKT were reduced after treatment.
  • Paradoxically, pEGFR was increased in EGFR-negative tumors post-treatment (P = .001).
  • Although markers were reduced in surrogate and tumor tissues in the patient with EGFR-positive tumor, no apparent associations were observed in patients with EGFR-negative tumor.
  • CONCLUSION: Erlotinib has inhibitory biologic effects on normal surrogate tissues and on an EGFR-positive tumor.
  • The lack of reduced tumor proliferation may be attributed to the heterogeneous expression of receptor in the EGFR-positive patient and absence of target in this cohort of heavily pretreated patients.
  • [MeSH-minor] Administration, Oral. Biomarkers / analysis. Endpoint Determination. Erlotinib Hydrochloride. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Mouth Mucosa / metabolism. Neoplasm Metastasis. Phosphorylation. Pilot Projects. Signal Transduction / drug effects. Skin / metabolism. Tomography, Emission-Computed


20. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl; 2002;(547):25-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment effects in patients with squamous cell carcinoma of the oral cavity.
  • Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9.
  • In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group.
  • Five-year cumulative survival rates showed significant differences between stage classifications (stage I = 91%, stage II = 73%, stage III = 63%, stage IV = 47%; p < 0.01) but not between tumor sites.
  • No significant difference in regional control rates was observed between the treatment groups.
  • The 5-year survival rate for patients with cervical recurrences after primary tumor resection was 70% (n = 15).
  • In contrast, the 5-year survival rate for patients with both primary tumor resection and neck dissection was 74% (n = 14) but no significant difference was observed between these 2 groups.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth / drug effects. Mouth / radiation effects. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Severity of Illness Index. Survival Rate


21. Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM: Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res; 2004 Aug 1;10(15):5038-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ki67, p53, and phosphorylated retinoblastoma protein (phospho-Rb) in paired tumor and buccal mucosa biopsies (obtained pre- and posttreatment) were examined by immunohistochemistry.
  • Nuclear staining with p53 increased and phospho-Rb decreased in 10 pairs of buccal mucosa biopsies posttreatment (P = 0.002 and P = 0.04, respectively).
  • The changes in p53 and phospho-Rb in buccal mucosa suggest that a biological effect with flavopiridol was achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Cyclin-Dependent Kinases / antagonists & inhibitors. Enzyme Inhibitors / administration & dosage. Flavonoids / administration & dosage. Piperidines / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Area Under Curve. Biomarkers, Tumor / metabolism. Biopsy. Clinical Trials as Topic. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Middle Aged. Mouth Mucosa / pathology. Mucous Membrane / pathology. Neoplasm Metastasis. Phosphorylation. Retinoblastoma Protein / biosynthesis. Time Factors. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297405.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Ki-67 Antigen; 0 / Piperidines; 0 / Retinoblastoma Protein; 0 / Taxoids; 0 / Tumor Suppressor Protein p53; 15H5577CQD / docetaxel; 45AD6X575G / alvocidib; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down






Advertisement